Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers - Concepedia

Concepedia

Publication | Open Access

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

DOI Full Paper Access

25

Citations

34

References

2024

Year

Allison M. Barrett, Zachary T. Britton, Rosa A. Carrasco, Shannon Breen, Maria A.S. Broggi, Amanda L. Hatke, Benjamin Clark, Chunning Yang, Sandrina Phipps, Lorenzo Burgos Ortiz,

Clinical Cancer Research

Abstract

AZD6422 was safe and efficacious in patient-derived, CLDN18.2-positive murine models of gastrointestinal cancers. Our data support further clinical development of AZD6422 for patients with these cancers.

References

	Year	Citations

Page 1